On January 26th, 2026, we held our third CureQ General Assembly, this time in Utrecht at Bar Beton. It was a packed day full of updates, discussions, and energy. A great way to kick off the new year together!
This was a moment to bring everyone in CureQ back together — researchers, clinicians, partners, patient organisations, and funders — to look back on what we achieved in our third year (2025), and to get inspired for the next phase. It was also our third meeting with the Advisory Board, where we had the chance to present our progress and receive their valuable feedback.
We started the day with a roundtable discussion. Then, after a nice lunch, each work package presented the progress made in the past year and we had fruitful discussions. Finally the Advisory Board met and provided valuable feedback about the progress of the project and suggestions for the upcoming period. As usual, we ended the day with a well-earned borrel.
Accomplishments
Thanks to the strong collaboration between teams, we’ve made some real progress:
- Isogenic Cell Models
- Generated and characterized panels of isogenic iPSC lines for Huntington’s Disease (HD), SCA1, and SCA3.
- Differentiated lines into neural progenitor cells and 2D/3D neuronal cultures; developed and optimized functional assays.
- Integrated advanced analysis scripts and tools for disease modelling.
- Patient Cohorts and Data Collection
- Continued recruitment and data collection, focusing on early-onset and intermediate allele carriers.
- Merged international datasets to enhance statistical power; initiated follow-up visits and biomarker analyses.
- Patient-Derived iPSC Models
- Identified patient pairs with similar CAG repeats but different ages of onset for iPSC generation.
- Began analysis of 3D organoid models for novel biomarker discovery.
- Therapeutic Strategies
- Developed and tested new modulators targeting protein aggregation and degradation pathways.
- Advanced synthesis of ubiquitinated huntingtin mimics and optimized reporter systems.
- Fostered collaborations for high-throughput imaging and mechanistic studies.
- Data Management
- Established a FAIR-compliant digital infrastructure and standardized metadata templates.
- Developed interactive dashboards and migrated analysis pipelines to Python for improved efficiency.
- Ethics and Societal Impact
- Conducted empirical studies on ethical, psychological, and societal implications of prognostic information.
- Disseminated findings to patient organizations and developed guidance for responsible AI use.
- Outreach and Education
- Launched new educational modules on cell culture, data analysis, and scientific integrity.
- Enhanced community engagement through events, social media, and collaboration with patient foundations.
All these steps bring us closer to our main goals: understanding and predicting disease onset and severity, and finding better treatment strategies.
